ArticleCancer immunology, immunotherapy : CII2026
Prediction of tumor-infiltrating lymphocytes through habitat radiomics and exploration of response mechanisms in neoadjuvant immunochemotherapy-treated lung cancer.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundNeoadjuvant immunochemotherapy (NAIC) induces tumor microenvironment remodeling in non-small cell lung cancer (NSCLC), presenting challenges for treatment response assessment. This study developed and validated a habitat radiomics approach for non-invasive prediction of tumor-infiltrating lymphocyte (TIL) status to evaluate NAIC response in NSCLC.
methodsThis retrospective study enrolled 238 NSCLC patients following NAIC for clinical analysis, of which 201 patients met criteria for radiomics analysis. Patients were classified into TIL-positive and TIL-negative groups based on pathological assessment. Post-treatment computed tomography (CT) images were analyzed using K-means clustering to identify tumor habitat sub-regions for radiomic feature extraction. Seven machine learning algorithms were evaluated for TIL status prediction. Model interpretability was assessed through SHapley Additive exPlanations (SHAP) analysis. Single-cell RNA sequencing (scRNA-seq) data were analyzed to compare major pathological response (MPR) and non-MPR tumor microenvironments through cell type annotation, differentiation trajectory analysis, and intercellular communication network analysis.
resultsPre-treatment neutrophil-to-lymphocyte ratio (NLR) showed association with pathological response in multivariable analysis. The radiomics cohort was randomly divided 7:3 into training (n = 140) and test (n = 61) sets. The Random Forest model achieved an area under the receiver operating characteristic curve (AUC) of 0.823 (95% CI: 0.694-0.932) in the test set, and the habitat radiomics model stratified patients into high and low recurrence risk groups. Single-cell analysis identified immunosuppressive features in non-responding tumors, characterized by expansion of SERPINB9 + regulatory T cells (Tregs) that regulated suppressive intercellular communication networks.
conclusionsThis study establishes a habitat radiomics model for non-invasive assessment of TIL status following neoadjuvant immunochemotherapy in NSCLC. The model shows reliable predictive performance and prognostic stratification capability, offering potential clinical utility for treatment response evaluation and patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.